OSTX · OS Therapies Inc
$1.66
0.00 (-0.28%)
At close · Sep 2
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$76.57M
Shares
46.13M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$28.75M
-223.7%
FY2025
Diluted EPS
-$0.98
+23.4%
FY2025
Operating Cash Flow
-$14.24M
-95.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $25.98M | $16.36M | $2.84M | $3.22M | |
| $11.63M | $12.34M | $3.97M | $1.13M | |
| $499.75K | $363.09K | $2780 | — | |
| -$37.61M | -$28.71M | -$6.81M | -$4.34M | |
| — | — | $2.05M | $3.45M | |
| $210 | $249 | — | $2 | |
| -$1.76M | -$48.14K | -$2.07M | -$3.45M | |
| -$39.37M | -$28.75M | -$8.88M | -$7.79M | |
| -$39.37M | -$28.75M | -$8.91M | -$7.92M | |
| USD/shares | -$1.08 | -$0.98 | -$1.28 | -$1.46 |
| USD/shares | -$1.08 | -$0.98 | -$1.28 | -$1.46 |
| shares | — | — | 12.38M | 5.43M |
| shares | — | 29.25M | 6.95M | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.58×
EV/EBIT
—
Peer median 12.89×
P/E (TTM)
—
Peer median 9.75×
Peer medians compare against the 283 similar-size Biotechnology companies (of 497 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Chief Operating Decision Maker | -$28,705,701 | -$6,813,846 | — |
| All Other Segments | — | — | -$4,342,645 |
Key facts
CIK
1795091
CUSIP
68764Y207
13F (30d)
27 filings
27 filers
Visit website
Investor relations